Alemtuzumab use in relapsed and refractory chronic lymphocytic leukemia. [corrected]

Abstract

A 62-year-old woman with chronic lymphocytic leukemia [corrected] (CLL) who initially presented with lymphocytosis and 13q deletion in 1996 now presents to the clinic for recommendations regarding relapsed disease. The patient has received multiple prior therapies, including single-agent fludarabine, fludarabine and rituximab, and bendamustine and rituximab. She now has recurrent lymphocytosis with a WBC count that has increased from 13,000 2 months ago to 115,000 today and a platelet count of 55,000 but no lymphadenopathy. In addition, your evaluation finds that she has acquired a 17p deletion.